An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
The study is to evaluate the efficacy of KL-A167 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification
Classical Hodgkin Lymphoma
DRUG: KL-A167
Overall Response Rate, Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by IRC per the Lugano Classification, Up to 2years
Progression-free Survival (PFS), From the first dose of KL-A167 to the date of PD or death, whichever occurs first, Up to 2years|Duration of Response (DOR), From the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first, Up to 2years|Overall Survival (OS), From the first dose of KL-A167 to the date of death, Up to 2years|Time to Response, From the date of the first dose of KL-A167 to the time the response criteria are first met, Up to 2years
The study is to evaluate the efficacy of KL-A167 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification